- recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
This study is testing a new drug, TAK-676, for adults with advanced solid cancers. It aims to see if TAK-676 is safe, how well it's tolerated, and how it works, both alone and with another cancer drug called Pembrolizumab (Keytruda).
Poland · France · Austria - active not recruitingPHASE2
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
This study looks at how well a medicine called larotrectinib works for children and young people with certain rare cancers that have a specific gene change (TRK fusion). It also checks for any side effects.
United States · Canada